SCHEMBL109045

SCHEMBL109045

O=C(CI)Nc1ccc(C(=O)ON2C(=O)CCC2=O)cc1

nearest known ligand 0.54

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.54
HPGD P15428 4/20 0.54
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
MAPT P10636 4/20 0.43
LMNA P02545 2/20 0.43
ALOX12 P18054 1/20 0.43
NPSR1 Q6W5P4 2/20 0.41
GLA P06280 1/20 0.40
ATM Q13315 1/20 0.40
TSHR P16473 1/20 0.40
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7769437 0.86 ALDH1A1 (0.54) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL14369503 0.86 ALDH1A1 (0.58) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL22203030 0.84 MEN1 (0.46) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL10076741 0.84 L3MBTL1 (0.45) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL3686150 0.84 ALDH1A1 (0.51) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL15907989 0.84 ALDH1A1 (0.48) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL19695817 0.83 ALDH1A1 (0.54) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL2633144 0.81 ALDH1A1 (0.44) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL13221517 0.81 ALDH1A1 (0.42) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL27609104 0.81 GSK3B (0.44) ALDH1A1HPGDMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3628 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122028938-A Pharmaceutical combination comprising an anti-CD 37 antibody maytansinoid conjugate and a BCL2 inhibitor or PI3K inhibitor 德彪药业国际股份公司 2026-05-12 CN claimed
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
EP-4678240-A2 BRIDGE LINKERS FOR CONJUGATION OF CELL-BINDING MOLECULES Hangzhou Dac Biotech Co., Ltd. (CN) 2026-01-14 EP claimed
EP-3319936-B1 BRIDGE LINKERS FOR CONJUGATION OF CELL-BINDING MOLECULES HANGZHOU DAC BIOTECH CO LTD (CN) 2025-12-17 EP claimed
US-20250339551-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2025-11-06 US claimed
EP-4642492-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
EP-4642484-A1 TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
EP-4592311-A2 ANTIBODIES Lonza Ltd (CH) 2025-07-30 EP claimed
US-12364767-B2 Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers HANGZHOU DAC BIOTECH CO., LTD. (CN) 2025-07-22 US claimed
WO-2025151464-A1 ALPHA-PARTICLE RADIONUCLIDE-ANTIBODY CONJUGATES FOR TREATMENT OF SOLID TUMORS THE JOHNS HOPKINS UNIVERSITY (US) 2025-07-17 WO claimed
US-20110195021-A1 CD20 ANTIBODIES AND USES THEREOF IMMUNOGEN INC. (US) 2011-08-11 US claimed
US-7989598-B2 Antibodies; tissue-targeted therapy; for treatment of tumors, autoimmune diseases, graft rejections, graft versus host disease, viral infections, parasite infections IMMUNOGEN INC. (US) 2011-08-02 US claimed
US-20080171856-A1 METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES AND METHODS OF MAKING SAID CONJUGATES IMMUNOGEN, INC. (US) 2008-07-17 US claimed
US-20080145374-A1 METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES AND METHODS OF MAKING SAID CONJUGATES IMMUNOGEN, INC. (US) 2008-06-19 US claimed
US-20080114153-A1 METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES AND METHODS OF MAKING SAID CONJUGATES IMMUNOGEN. INC. (US) 2008-05-15 US claimed
EP-1689846-A2 METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES, AND METHODS OF MAKING SAID CONJUGATES Immunogen, Inc. (US) 2006-08-16 EP claimed
EP-1328811-B1 HCV MOSAIC ANTIGEN COMPOSITION MEDMIRA INC (CA) 2005-08-31 EP claimed
US-20050169933-A1 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates IMMUNOGEN, INC. 2005-08-04 US claimed
WO-2005037992-A2 METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES, AND METHODS OF MAKING SAID CONJUGATES IMMUNOGEN, INC. (US) 2005-04-28 WO claimed
WO-1994000600-A1 SOLID SUPPORTS FOR NUCLEIC ACID HYBRIDIZATION ASSAYS MICROPROBE CORPORATION (US) 1994-01-06 WO claimed